Advances in Molecular Subtype-Based Precision Therapy and Strategies to Overcome Resistance in Breast Cancer

Main Article Content

Yeyao Lu
Kangda College, Institute of Nanjing Medical University, Lianyungang, Jiangsu, China

DOI: https://doi.org/10.70267/shbe.2026179187

Keywords

breast cancer, molecular subtypes, precision therapy, resistance mechanisms, tumor heterogeneity

Abstract

Breast cancer is a leading cause of cancer -related morbidity and mortality, characterized by significant biological and molecular heterogeneity. Molecular subtypes —including luminal A, luminal B, HER2 - enriched, and triple -negative—inform prognosis and guide prec ision therapies. Despite advances with endocrine agents, HER2-targeted therapies, PARP inhibitors, and immune checkpoint inhibitors, therapeutic resistance remains a major challenge, driven by intratumoral heterogeneity, cancer stem cell plasticity, and tumor microenvironmental factors. Genomic profiling, liquid biopsies, combination and adaptive strategies, and next-generation antibody-drug conjugates are emerging to overcome resistance and optimize outcomes. Additionally, novel immunotherapies and artific ial intelligence (AI) –assisted decision -making support individualized treatment selection. This review summarizes recent advances, from molecular characterization to precision-guided interventions and strategies to counteract resistance, and emphasizes the integration of biological insights into personalized breast cancer management.

Abstract 64 | PDF Downloads 37

References

  • [1] Omar Freihat, David Sipos & Arpad Kovacs. (2025). Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data.Frontiers in Public Health,13,1622954-1622954. https://doi.org/10.3389/FPUBH.2025.1622954.
  • [2] Lim Zi Lin, Ho Peh Joo, Khng Alexis Jiaying, Yeoh Yen Shing, Ong Amanda Tse Woon, Tan Benita Kiat Tee... & Hartman Mikael. (2022). Mammography screening is associated with more favourabl e breast cancer tumour characteristics and better overall survival: case -only analysis of 3739 Asian breast cancer patients.BMC Medicine,20(1),239-239. https://doi.org/10.1186/S12916-022-02440-Y.
  • [3] Swain Sandra M, Shastry Mythili, & Hamilton Erika. (2022). Targeting HER2 -positive breast cancer: advances and future directions. Nature Reviews. Drug Discovery, 22(2), 101 -126. https://doi.org/10.1038/S41573-022-00579-0.
  • [4] Curtis Christina, Shah Sohrab P, Chin Suet-Feung, Turashvili Gulisa, Rueda Oscar M, Dunning Mark J... & Aparicio Samuel. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature,486(7403),346-52. https://doi.org/10.1038/nature10983.
  • [5] Daniel C. Koboldt, Robert S. Fulton, Michael D. McLellan, Heather Schmidt, Joelle Kalicki -Veizer, Joshua F. McMichael... & Richard K. Wilson. (2012). Comprehensive molecular portraits of human breast tumours. Nature,490(7418),61-70. https://doi.org/10.1038/nature11412.
  • [6] J. Prat. (2014). The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type. Annals of Oncology,25(7),1255 -1258. https://doi.org/10.1093/annonc/mdu160.
  • [7] Yates, Lucy R., & Campbell, Peter J.(2012). Evolution of the cancer genome. Nature Reviews. Genetics, 13(11), 795-806. https://doi.org/10.1038/nrg3317.
  • [8]Nicholas McGranahan & Charles Swanton.(2017).Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.Cell,168(4),613-628. https://doi.org/10.1016/j.cell.2017.01.018.
  • [9] Wu Sunny Z., Al Eryani Ghamdan, Roden Daniel Lee, Junankar Simon, Harvey Kate, Andersson Alma... & Swarbrick Alexander . (2021). A single -cell and spatially resolved atlas of human breast cancers.Nature Genetics,53(9),1334-1347. https://doi.org/10.1038/S41588-021-00911-1.
  • [10] Sidharth V. Puram, Itay Tirosh, Anuraag S. Parikh, Anoop P. Patel, Keren Yizhak, Shawn Gillespie... & Bradley E. Bernstein. (2017). Single -Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer.Cell,171(7),1611 -1624.e24. https://doi.org/10.1016/j.cell.2017.10.044.
  • [11] Sreenath V. Sharma, Diana Y. Lee, Bihua Li, Margaret P. Quinlan, Fumiyuki Takahashi, Shyamala Maheswaran... & Jeff Settleman.(2010).A Chromatin -Mediated Reversible Drug -Tolerant State in Cancer Cell Subpopulations.Cell, 141(1), 69-80. https://doi.org/10.1016/j.cell.2010.02.027.
  • [12] Joseph Wee. (2012). Nasopharyngeal cancer: a promising future.Lancet Oncology,13(2),116 -118. https://doi.org/10.1016/S1470-2045(11)70321-7.
  • [13] Junttila Melissa R. & de Sauvage Frederic J. (2013). Influence of tumour micro -environment heterogeneity on therapeutic response. Nature, 501(7467), 346-54. https://doi.org/10.1038/nature12626.
  • [14] Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature reviews Clinical oncology, 14(9), 531-548.
  • [15] O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., ... & Turner, N. C. (2018). The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer discovery, 8(11), 1390-1403.
  • [16] Segovia, M., Russo, S., Jeldres, M., Mahmoud, Y. D., Perez, V., Duhalde, M., ... & Hill, M. (2019). Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation. Cancer cell, 35(5), 767-781.
  • [17] Pickup Michael W, Mouw Janna K & Weaver Valerie M. (2014). The extracellular matrix modulates the hallmarks of cancer. EMBO reports, 15(12), 1243-53. https://doi.org/10.15252/embr.201439246.
  • [18] Bonnans, C., Chou, J., & Werb, Z. (2014). Remodelling the extracellular matrix in development and disease. Nature Reviews Molecular Cell Biology, 15(12), 786-801.
  • [19] Daniel Öhlund, Ela Elyada & David Tuveson . (2014). Fibroblast heterogeneity in the cancer wound. Fibroblast heterogeneity in cancer.Journal of Experimental Medicine,211(8),1503 -1523. https://doi.org/10.1084/jem.20140692.
  • [20] Sahai Erik, Astsaturov Igor, Cukierman Edna, DeNardo David G, Egeblad Mikala, Evans Ronald M... & Werb Zena. (2020). A framework for advancing our understanding of cancer -associated fibroblasts. Nature Reviews. Cancer,20(3),174-186. https://doi.org/10.1038/s41568-019-0238-1.
  • [21] Bin-Zhi Qian & Jeffrey W. Pollard. (2010). Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell, 141(1), 39-51. https://doi.org/10.1016/j.cell.2010.03.014.
  • [22] Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016). Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature reviews Clinical oncology, 13(4), 228-241.
  • [23] Gabrilovich Dmitry I & Nagaraj Srinivas. (2009). Myeloid -derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology,9(3),162-74. https://doi.org/10.1038/nri2506.
  • [24] Diehn Maximilian, Cho Robert W, Lobo Neethan A, Kalisky Tomer, Dorie Mary Jo, Kulp Angela N... & Clarke, Michael F. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458(7239), 780-3. https://doi.org/10.1038/nature07733.
  • [25] Pattabiraman Diwakar R & Weinberg Robert A.(2014). Tackling the cancer stem cells - what challenges do they pose?. Nature Reviews. Drug Discovery, 13(7), 497-512. https://doi.org/10.1038/nrd4253.
  • [26] Sosa Marí a Soledad,Bragado Paloma & Aguirre-Ghiso Julio A.(2014).Mechanisms of disseminated cancer cell dormancy: an awakening field. Nature Reviews. Cancer,14(9),611 -22. https://doi.org/10.1038/nrc3793.
  • [27] Vicki Plaks, Niwen Kong & Zena Werb. (2015). The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?.Cell Stem Cell,16(3),225 -238. https://doi.org/10.1016/j.stem.2015.02.015.
  • [28] Takebe Naoko, Harris Pamela J, Warren Ronald Q & Ivy S Percy. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Reviews. Clini cal oncology,8(2),97 -106. https://doi.org/10.1038/nrclinonc.2010.196.
  • [29] Naujokat Cord, Steinhart Roman, & Huczynski Adam. (2012). Salinomycin as a Drug for Targeting Human Cancer Stem Cells.Journal of Biomedicine and Biotechnology,2012(XI),950658 - 950658. https://doi.org/10.1155/2012/950658.
  • [30] Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., & Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen -treated, node-negative breast cancer. The New England journal of medicine, 351(27), 2817–2826. https://doi.org/10.1056/NEJMoa041588
  • [31] Sparano Joseph A, Gray Robert J, Makower Della F, Pritchard Kathleen I, Albain Kathy S, Hayes Daniel F... & Sledge Georg. (2018). Adjuvant Chemotherapy Guided by a 21 -Gene Expression Assay in Breast Cancer. The New England Journal of Medicine, 379(2), 111 -121. https://doi.org/10.1056/NEJMoa1804710.
  • [32]van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., & Friend, S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530–536. https://doi.org/10.1038/415530a
  • [33] Cardoso Fatima, van't Veer Laura J, Bogaerts Jan, Slaets Leen, Viale Giuseppe, Delaloge Suzette... & Piccart Martine. (2016).70 -Gene Signature as an Aid to Treatment Decisions in Early -Stage Breast Cancer. The New England Journal of Medicine, 375(8), 717 -29. https://doi.org/10.1056/NEJMoa1602253.
  • [34] Parker Joel S, Mullins Michael, Cheang Maggie C U, Leung Samuel, Voduc David, Vickery Tammi... & Bernard Philip S. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology,27(8),1160-7. https://doi.org/10.1200/JCO.2008.18.1370.
  • [35] Dubsky P, Brase J C, Jakesz R, Rudas M, Singer C F, Greil R... & Filipits M. (2013). The EndoPredict score provides prognostic information on late dis tant metastases in ER+/HER2 - breast cancer patients. British Journal of Cancer, 109(12), 2959-64. https://doi.org/10.1038/bjc.2013.671.
  • [36] Paik Soonmyung, Shak Steven, Tang Gong, Kim Chungyeul, Baker Joffre, Cronin Maureen... & Wolmark Norman. (2004). A multigene assay to predict recurrence of tamoxifen -treated, node - negative breast cancer. The New England journal of medicine,351(27),2817-26.
  • [37] Robson Mark, Im Seock -Ah, S enkus Elżbieta, Xu Binghe,Domchek Susan M,Masuda Norikazu... & Conte Pierfranco (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England journal of medicine,377(6),523 -533. https://doi.org/10.1056/NEJMoa1706450.
  • [38] Verma Sunil, Miles David, Gianni Luca, Krop Ian E, Welslau Manfred, Baselga José ... & Blackwell Kim. (2012). Trastuzumab emtansine for HER2 -positive advanced breast cancer. The New England journal of medicine,367(19),1783-91. https://doi.org/10.1056/NEJMoa1209124.
  • [39] Lambert, John M., & Chari, Ravi V J.(2014). Ado -trastuzumab Emtansine (T -DM1): an antibody -drug conjugate (ADC) for HER2 -positive breast cancer. Journal of medicinal chemistry,57(16),6949 -64. https://doi.org/10.1021/jm500766w.
  • [40]Corté s, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L. M., Petry, V., Chung, C. F., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Huang, C. S., Kim, J. H., Chiu, J. W. Y., Pedrini, J. L., Lee, C., Liu, Y., … DESTINY -Breast03 Trial Investigators (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. The New England journal of medicine, 386(12), 1143–1154. https://doi.org/10.1056/NEJMoa2115022
  • [41] Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kü mmel, S., Bergh, J., ... & O’Shaughnessy, J. (2020). Pembrolizumab for early triple -negative breast cancer. New England Journal of Medicine , 382(9), 810- 821.
  • [42] Litton Jennifer K, Rugo Hope S, Ettl Johannes, Hurvitz Sara A, Gonç alves Anthony, Lee Kyung-Hun... & Blum Joanne L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England Journal of Medicine, 379(8), 753 -763. https://doi.org/10.1056/NEJMoa1802905.
  • [43] Loizidis Sotiris, Stanciu Maria Alexandra, & Ignatiadis Michail. (2025). Liquid biopsy in breast cancer: promises and challenges. Current Opinion in Oncology, https://doi.org/10.1097/CCO.0000000000001168.
  • [44] Muhammad Umer Khan, Arooj Khawar, Muhammad Ikram Ullah, Muhammad Adnan Shan, Luca Falzone, Massimo Libra... & Daniela Calina (2025). Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment, and monitoring. Molecular and cellular biochemistry,480(11),5555-5569. https://doi.org/10.1007/S11010-025-05343-7.
  • [45] Brittney S. Zimmerman & Francisco J. Esteva. (2024). Next -Generation HER2 -Targeted Antibody – Drug Conjugates in Breast Cancer.Cancers,16(4), https://doi.org/10.3390/CANCERS16040800.
  • [46] Meriem Grairi & Marc Le Borgne (2024). Antibody-drug conjugates: prospects for the next generation. Drug discovery today, 29(12), 104241. https://doi.org/10.1016/J.DRUDIS.2024.104241.
  • [47] Akbar Ali,Mansoor Alghamdi, Shahira Sofea Marzuki, Tengku Ahmad Damitri Al Astani Tengku Din, Muhamad Syahmi Yamin, Malek Alrashidi... & Naveed Ahmed. (2025). Exploring AI Approaches for Breast Cancer Detection and Diagnosis: A Review Article. Breast cancer (Dove Medical Press),17,927 - 947. https://doi.org/10.2147/BCTT.S550307.

Article Sidebar

PDF
Published
Aug 11, 2026
Conference Proceedings Volume
Vol. 18 (2026): Proceedings of 2026 International Conference on Smart Healthcare and Biomedical Engineering (ICSHBE 2026)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Lu, Yeyao. “Advances in Molecular Subtype-Based Precision Therapy and Strategies to Overcome Resistance in Breast Cancer”. Exploring Science Academic Conference Series, vol. 18, Aug. 2026, pp. 179-87, https://doi.org/10.70267/shbe.2026179187.